Resumen
El tirofibán es un derivado no peptídico de la tirosina que pertenece al grupo de los inhibidores de la glucoproteína IIb/IIIa junto a la eptifibatida (ambos de molécula pequeña) y el abciximab. A pesar de una alta afinidad por el receptor IIb/IIIa, se disocia mucho antes que el abciximab, con lo que su acción se revierte en pocas horas. Clásicamente, su uso se restringía a pacientes con síndrome coronario agudo sin elevación del segmento ST que iban a ser sometidos a angioplastia coronaria, aunque recientemente y debido a una modificación de la dosis utilizada, se ha comenzado a usar con éxito tanto en la angioplastia electiva de alto riesgo como en la angioplastia primaria, con resultados en ambas indicaciones similares al abciximab, el fármaco habitualmente usado en estos contextos clínicos, y a un coste menor.
Palabras clave
Tirofibán
Abciximab
Inhibidores de la glucoproteína IIb/IIIa
Intervención coronaria percutánea
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
R.W. Colman, A.W. Clowes, J.N. George, S.Z. Goldhaber, V.J. Marder.
Overview of hemostasis..
Hemostasis and thrombosis, 4.a ed., Lippincott Williams & Wilkins, pp. 3-16
[2.]
R.M. Scarborough, N.S. Kleiman, D.R. Phillips.
Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?.
Circulation, (1999), 100 pp. 437-444
[3.]
E.J. Topol, T.V. Byzova, E.F. Plow.
Platelet GPIIb-IIIa blockers.
Lancet, (1999), 353 pp. 227-231
[4.]
M. Lele, M. Sajid, N. Wajih, G.A. Stouffer.
Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Circulation, (2001), 104 pp. 582-587
[5.]
M. Roffi, D.P. Chew, D. Mukherjee, D.L. Bhatt, J.A. White, D.J. Moliterno, et al.
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
Eur Heart J, (2002), 23 pp. 1441-1448
[6.]
E. Boersma, K.M. Akkerhuis, P. Théroux, R.M. Califf, E.J. Topol, M.L. Simoons.
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Circulation, (1999), 100 pp. 2045-2048
[7.]
The PRISM-PLUS Study Investigators.
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms.
N Engl J Med, (1998), 338 pp. 1488-1497
[8.]
G.W. Stone, M.E. Bertrand, J.W. Moses, E.M. Ohman, A.M. Lincoff, J.H. Ware, et al.
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. The ACUITY Timing trial.
JAMA, (2007), 297 pp. 591-602
[9.]
R. Giugliano, J. White, C. Bode, P. Armstrong, G. Montalescot, B. Lewis, et al.
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
N Engl J Med, (2009), 360 pp. 2176-2190
[10.]
J.P. Bassand, C.W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernández-Avilés, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary síndromes. The Task Force for the Diagnosis and Treatment of Non-STSegment Elevation Acute Coronary Syndromes of the European Society of Cardiology.
Eur Heart J, (2007), 28 pp. 1598-1660
[11.]
J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, D.E. Casey, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction).
Circulation, (2007), 116 pp. e148-e304
[12.]
W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, et al.
Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J, (2010), 31 pp. 2051-2555
[13.]
The RESTORE Investigators.
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.
Circulation, (1997), 96 pp. 1445-1453
[14.]
E.J. Topol, D.J. Moliterno, H.C. Herrmann, for the TARGET Trial Investigators.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abiciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
N Engl J Med, (2001), 344 pp. 1888-1894
[15.]
G.W. Stone, D.J. Moliterno, M. Bertrand, F.J. Neumann, H.C. Herrmann, E.R. Powers, et al.
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing stenting: the TARGET trial.
Circulation, (2002), 105 pp. 2347-2354
[16.]
A.W. Bonz, B. Lengenfelder, J. Strotmann, S. Held, O. Turschner, K. Harre, C. Wacker, et al.
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
J Am Coll Cardiol, (2002), 40 pp. 662-668
[17.]
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, et al.
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. The ADVANCE Trial.
J Am Coll Cardiol, (2004), 44 pp. 14-19
[18.]
G.B. Danzi, C. Capuano, M. Sesana, R. Baglini.
Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention.
Curr Med Res Opin, (2003), 19 pp. 1-6
[19.]
L. Bolognese, G. Falsini, F. Liistro, P. Angioli, K. Ducci, T. Taddei, et al.
Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
J Am Coll Cardiol, (2006), 47 pp. 522-528
[20.]
S. Rasoul, J.P. Ottervanger, M.J. De Boer, K. Miedema, J.C. Hoorntje, M. Gosselink, et al.
A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
Eur Heart J, (2006), 27 pp. 1401-1407
[21.]
B.T. Ivandic, K. Kurz, F. Keck, P. Staritz, S. Lehrke, H.A. Katus, et al.
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Thromb Haemost, (2008), 100 pp. 648-654
[22.]
M. Valgimigli, G. Campo, N. De Cesare, E. Meliga, P. Vranckx, A. Furgieri, et al.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Circulation, (2009), 119 pp. 3215-3222
[23.]
G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, et al.
Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up: platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
N Engl J Med, (2001), 344 pp. 1895-1903
[24.]
G.W. Stone, C.L. Grines, D.A. Cox, E. Garcia, J.E. Tcheng, J.J. Griffin, et al.
Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction.
N Engl J Med, (2002), 346 pp. 957-966
[25.]
D. Antoniucci, A. Rodriguez, A. Hempel, R. Valenti, A. Migliorini, F. Vigo, et al.
A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.
J Am Coll Cardiol, (2003), 42 pp. 1879-1885
[26.]
D. Antoniucci, A. Migliorini, G. Parodi, R. Valenti, A. Rodriguez, A. Hempel, et al.
Abciximab supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone.
Circulation, (2004), 109 pp. 1704-1706
[27.]
G. De Luca, H. Suryapranata, G.W. Stone, D. Antoniucci, J.E. Tcheng, F.J. Neumann, et al.
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
JAMA, (2005), 293 pp. 1759-1765
[28.]
G. Montalescot, D. Antoniucci, A. Kastrati, F.J. Neumann, M. Borentain, A. Migliorini, et al.
Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients’ data with long-term follow-up.
Eur Heart J, (2007), 28 pp. 443-449
[29.]
D.J. Schneider, H.C. Herrmann, N. Lakkis, F. Aguirre, Y. Wan, A. Aggarwal, et al.
Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
Am J Cardiol, (2002), 90 pp. 1421-1423
[30.]
N.M. Ernst, H. Suryapranata, K. Miedema, R.J. Slingerland, J.P. Ottervanger, J.C. Hoorntje, et al.
Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
J Am Coll Cardiol, (2004), 44 pp. 1187-1193
[31.]
D.E. Cutlip, M.J. Ricciardi, F.S. Ling, J.P. Carrozza, V. Dua, J. Garringer, et al.
Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.
Am J Cardiol, (2003), 92 pp. 977-980
[32.]
D.P. Lee, N.A. Herity, B.L. Hiatt, W.F. Fearon, M. Rezaee, A.J. Carter, et al.
Tirofiban given in the emergency room before primary angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial.
Circulation, (2003), 107 pp. 1497-1501
[33.]
A.W. Van’t Hof, N. Ernst, M.J. De Boer, R. De Winter, E. Boersma, T. Bunt, et al.
Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
Eur Heart J, (2004), 25 pp. 837-846
[34.]
G. De Luca, J.J. Smit, N. Ernst, H. Suryapranata, J.P. Ottervanger, J.C. Hoorntje, et al.
Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.
Thromb Haemost, (2005), 93 pp. 820-823
[35.]
A. Emre, E. Ucer, K. Yesilcimen, T. Bilsel, D. Oz, N. Sayar, et al.
Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarctrelated artery stenting.
Cardiology, (2006), 106 pp. 264-269
[36.]
M. Valgimigli, G. Percoco, P. Malagutti, G. Campo, F. Ferrari, D. Barbieri, et al.
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stents for acute myocardial infarction: a randomized trial.
JAMA, (2005), 293 pp. 2109-2117
[37.]
G.B. Danzi, M. Sesana, C. Capuano, L. Mauri, P. Berra Centurini, R. Baglini.
Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
Am J Cardiol, (2004), 94 pp. 35-39
[38.]
J. Shen, Q. Zhang, R.Y. Zhang, J.S. Zhang, J. Hu, Z.K. Yang, et al.
Clinical benefits of adjunctive tirofiban therapy in patients with acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Coron Artery Dis, (2008), 19 pp. 271-277
[39.]
J.W. Van Werkum, W.B.M. Gerritsen, J.C. Kelder, C.M. Hackeng, S.M. Ernst, V.H. Deneer, et al.
Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.
Neth Heart J, (2007), 11 pp. 375-381
[40.]
X.H. Fu, Q.Q. Hao, X.W. Jia, W.Z. Fan, X.S. Gu, W.L. Wu, et al.
Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Chin Med J, (2008), 121 pp. 522-527
[41.]
M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, et al.
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
JAMA, (2008), 299 pp. 1788-1799
[42.]
A.W. Van’t Hof, C. Hamm, S. Rasoul, S. Guptha, J.F. Paolini, J.M. Ten Berg.
Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design.
Euro Interv, (2007), 3 pp. 371-380
[43.]
Hamm C, Van’t Hof AW, Ten Berg J, et al. Results of the On-TIME 2 trial: prehospital tirofiban in STEMI [abstract no. 413–5]. American College of Cardiology 57th Annual Scientific Sessions; 2008 Mar 29-Apr 1; Chicago (IL).
[44.]
A.W. Van’t Hof, J. Ten Berg, T. Heestermans, T. Dill, R.C. Funck, W. Van Werkum, et al.
Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME) 2: a multicentre, double-blind, randomised controlled trial.
Lancet, (2008), 372 pp. 537-546
[45.]
A. Marzocchi, A. Manari, G. Piovaccari, on behalf of the FATA Investigators.
Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the Facilitated Angioplasty with Tirofiban or Abciximab (FATA) in ST-elevation myocardial infarction trial.
Eur Heart J, (2008), 29 pp. 2972-2980
[46.]
G. De Luca, M. Gibson, F. Bellandi, S. Murphy, M. Maioli, M. Noc, et al.
Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patients’ data meta-analysis.
Heart, (2008), 94 pp. 1548-1558
[47.]
L. Janssens, C. Van Haesendonck, A.J. Van Boven, J. Lu, L. Damaraju, E.S. Barnathan, et al.
Early treatment of ST elevation myocardial infarction with abciximab or with abciximab and reteplase reduces the incidence of cardiogenic shock: results of the FINESSE trial [abstract].
Eur Heart J, (2008), 29 pp. 136
[48.]
A.W. Van’t Hof, A. Liem, M.J. De Boer, F. Zijlstra.
Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group.
Lancet, (1997), 350 pp. 615-619
[49.]
B.G. Angeja, M. Gunda, S.A. Murphy, B.E. Sobel, A.C. Rundle, M. Syed, et al.
TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging.
Circulation, (2002), 105 pp. 282-285
[50.]
G. De Luca, A.C. Maas, A.W. Van’t Hof, J.P. Ottervanger, J.C. Hoorntje, A.T. Gosselink, et al.
Impact of ST segment depression resolution on mortality after successful mechanical reperfusion in patients with ST-segment elevation acute myocardial infarction.
Am J Cardiol, (2005), 95 pp. 234-236
[51.]
R.D. Anderson, H.D. White, E.M. Ohman, G.S. Wagner, M.W. Krucoff, P.W. Armstrong, et al.
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries.
Am Heart J, (2002), 144 pp. 81-88
[52.]
J.M. Ten Berg, A.W. Van’t Hof, T. Dill, T. Heestermans, J.W. Van Werkum, A. Mosterd, et al.
Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with st-segment elevation myocardial infarction on short- and long-term clinical outcome.
J Am Coll Cardiol, (2010), 55 pp. 2446-2455
[53.]
G. De Luca, G. Ucci, E. Cassetti, P. Marino.
Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty. A meta-analysis.
J Am Coll Cardiol, (2009), 53 pp. 1668-1673
[54.]
F. Ottani, L. La Vecchia, M. De Vita, O. Catapano, F. Tarantino, M. Galvani.
Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.
Am J Cardiol, (2010), 106 pp. 167-174
[55.]
H.S. Gurm, U. Tamhane, P. Meier, P.M. Grossman, S. Chetcuti, E.R. Bates.
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Circ Cardiovasc Interv, (2009), 2 pp. 230-236
[56.]
F.J. Kushner, M. Hand, S.C. Smith, S.B. King, J.L. Anderson, E.M. Antman, et al.
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol, (2009), 54 pp. 2205-2241
[57.]
M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi, A.W. Van’t Hof, G. Campo, C. Hamm, et al.
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
Eur Heart J, (2010), 31 pp. 35-49
Copyright ©
2011. Sociedad Española de Cardiología